Chemistry and Structure-Activity Relationships of the Psychotomimetics
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Index Vol. 12-15
353 INDEX VOL. 12-15 Die Stichworte des Sachregisters sind in der jeweiligen Sprache der einzelnen Beitrage aufgefiihrt. Les termes repris dans la Table des matieres sont donnes selon la langue dans laquelle l'ouvrage est ecrit. The references of the Subject Index are given in the language of the respective contribution. 14 AAG (Alpha-acid glycoprotein) 120 14 Adenosine 108 12 Abortion 151 12 Adenosine-phosphate 311 13 Abscisin 12, 46, 66 13 Adenosine-5'-phosphosulfate 148 14 Absorbierbarkeit 317 13 Adenosine triphosphate 358 14 Absorption 309, 350 15 S-Adenosylmethionine 261 13 Absorption of drugs 139 13 Adipaenin (Spasmolytin) 318 14 - 15 12 Adrenal atrophy 96 14 Absorptionsgeschwindigkeit 300, 306 14 - 163, 164 14 Absorptionsquote 324 13 Adrenal gland 362 14 ACAI (Anticorticocatabolic activity in 12 Adrenalin(e) 319 dex) 145 14 - 209, 210 12 Acalo 197 15 - 161 13 Aceclidine (3-Acetoxyquinuclidine) 307, 13 {i-Adrenergic blockers 119 308, 310, 311, 330, 332 13 Adrenergic-blocking activity 56 13 Acedapsone 193,195,197 14 O(-Adrenergic blocking drugs 36, 37, 43 13 Aceperone (Acetabutone) 121 14 {i-Adrenergic blocking drugs 38 12 Acepromazin (Plegizil) 200 14 Adrenergic drugs 90 15 Acetanilid 156 12 Adrenocorticosteroids 14, 30 15 Acetazolamide 219 12 Adrenocorticotropic hormone (ACTH) 13 Acetoacetyl-coenzyme A 258 16,30,155 12 Acetohexamide 16 14 - 149,153,163,165,167,171 15 1-Acetoxy-8-aminooctahydroindolizin 15 Adrenocorticotropin (ACTH) 216 (Slaframin) 168 14 Adrenosterone 153 13 4-Acetoxy-1-azabicyclo(3, 2, 2)-nonane 12 Adreson 252 -
(12) United States Patent (10) Patent No.: US 8,940,728 B2
USOO894.0728B2 (12) UnitedO States Patent (10) Patent No.: US 8,940,728 B2 Mash et al. (45) Date of Patent: Jan. 27, 2015 (54) SUBSTITUTED NORIBOGAINE 5,152.994. A 10/1992 Lotsof 5,283,247 A 2f1994 Dwivedi et al. (71) Applicant: DemeRx, Inc., Miami, FL (US) 5,316,7595,290,784. A 3/19945/1994 Quetal.Rose et al. 5,382,657 A 1/1995 K. tal. (72) Inventors: Deborah C. Mash, Miami, FL (US); 5,426,112 A 6, 1995 ity a Richard D. Gless, Jr., Oakland, CA 5,552,406 A 9, 1996 Mendelson et al. (US); Robert M. Moriarty, Michiana 5,574,052 A 1 1/1996 Rose et al. Shores, IN (US) 5,578,645 A 11/1996 Askanazi et al. s 5,580,876 A 12/1996 Crain et al. 5,591,738 A 1, 1997 LotSof (73) Assignee: DemeRx, Inc., Miami, FL (US) 5,618,555 A 4/1997 Tokuda et al. - 5,703,101 A 12/1997 Rose et al. (*) Notice: Subject to any disclaimer, the term of this 5,726, 190 A 3, 1998 Rose et al. patent is extended or adjusted under 35 S.S.; A s 3. th. 1 U.S.C. 154(b)(b) bybV 144 davs.ayS 5,865.444.wwk A 2/1999 KempfetOSe et al. al. 5,925,634 A 7/1999 Olney (21) Appl. No.: 13/732,751 5,935,975 A 8/1999 Rose et al. 6,211,360 B1 4/2001 Glicket al. (22) Filed: Jan. 2, 2013 6,291.675 B1 9/2001 Coop et al. -
The Alkaloids: Chemistry and Biology
CONTRIBUTORS Numbers in parentheses indicate the pages on which the authors’ contributions begin. B. EMMANUEL AKINSHOLA (135), Department of Pharmacology, College of Medicine, Howard University, Washington, DC 20059, eakinshola@ howard.edu NORMA E. ALEXANDER (293), NDA International, 46 Oxford Place, Staten Island, NY 10301, [email protected] SYED F. ALI (79, 135), Division of Neurotoxicology, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] KENNETH R. ALPER (1, 249), Departments of Psychiatry and Neurology, New York University School of Medicine, 550 First Avenue, New York, NY 10016, [email protected] MICHAEL H. BAUMANN (79), Clinical Psychopharmacology Section, Intra- mural Research Program, NIDA, National Institutes of Health, Baltimore, MD 21224, [email protected] DANA BEAL (249), Cures-not-Wars, 9 Bleecker Street, New York, NY 10012, [email protected] ZBIGNIEW K. BINIENDA (193), Division of Neurotoxicology, National Cen- ter for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, [email protected] WAYNE D. BOWEN (173), Laboratory of Medicinal Chemistry, NIDDK, NIH, Building 8 B1-23, 8 Center Drive, MSC 0820, Bethesda, MD 20892, [email protected] FRANK R. ERVIN (155), Department of Psychiatry and Human Genetics, McGill University, Montreal, Quebec H3A 2T5, Canada, md18@musica. mcgill.ca JAMES W. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, jwfi@midway. uchicago.edu xi xii CONTRIBUTORS RENATE L. FERNANDEZ (235), Department of Anthropology, University of Chicago, 1126 E. 59th Street, Chicago, IL 60637, rlf2@midway. uchicago.edu GEERTE FRENKEN (283), INTASH, P.O. -
Alkaloids with Anti-Onchocercal Activity from Voacanga Africana Stapf (Apocynaceae): Identification and Molecular Modeling
molecules Article Alkaloids with Anti-Onchocercal Activity from Voacanga africana Stapf (Apocynaceae): Identification and Molecular Modeling Smith B. Babiaka 1,2,*, Conrad V. Simoben 3 , Kennedy O. Abuga 4, James A. Mbah 1, Rajshekhar Karpoormath 5 , Dennis Ongarora 4 , Hannington Mugo 4, Elvis Monya 6, Fidelis Cho-Ngwa 6, Wolfgang Sippl 3 , Edric Joel Loveridge 7,* and Fidele Ntie-Kang 1,3,8,* 1 Department of Chemistry, Faculty of Science, University of Buea, P.O. Box 63, Buea CM-00237, Cameroon; [email protected] 2 AgroEco Health Platform, International Institute of Tropical Agriculture, Cotonou, Abomey-Calavi BEN-00229, Benin 3 Institute for Pharmacy, Martin-Luther-Universität Halle-Wittenberg, Kurt-Mothes-Str. 3, 06120 Halle, Germany; [email protected] (C.V.S.); [email protected] (W.S.) 4 Department of Pharmaceutical Chemistry, School of Pharmacy, University of Nairobi, Nairobi P.O. Box 19676–00202, Kenya; [email protected] (K.O.A.); [email protected] (D.O.); [email protected] (H.M.) 5 Department of Pharmaceutical Chemistry, School of Chemistry, University of KwaZulu-Natal, Durban 4001, South Africa; [email protected] 6 ANDI Centre of Excellence for Onchocerciasis Drug Research, Biotechnology Unit, Faculty of Science, University of Buea, P.O. Box 63, Buea CM-00237, Cameroon; [email protected] (E.M.); fi[email protected] (F.C.-N.) 7 Department of Chemistry, Swansea University, Singleton Park, Swansea SA2 8PP, UK 8 Institute of Botany, Technical University of Dresden, 01217 Dresden, Germany * Correspondence: [email protected] or [email protected] (S.B.B.); Citation: Babiaka, S.B.; Simoben, C.V.; [email protected] (E.J.L.); ntiekfi[email protected] or fi[email protected] (F.N.-K.) Abuga, K.O.; Mbah, J.A.; Karpoormath, R.; Ongarora, D.; Abstract: A new iboga-vobasine-type isomeric bisindole alkaloid named voacamine A (1), along with Mugo, H.; Monya, E.; Cho-Ngwa, F.; eight known compounds—voacangine (2), voacristine (3), coronaridine (4), tabernanthine (5), iboxy- Sippl, W.; et al. -
Adverse Reactions to Hallucinogenic Drugs. 1Rnstttutton National Test
DOCUMENT RESUME ED 034 696 SE 007 743 AUTROP Meyer, Roger E. , Fd. TITLE Adverse Reactions to Hallucinogenic Drugs. 1rNSTTTUTTON National Test. of Mental Health (DHEW), Bethesda, Md. PUB DATP Sep 67 NOTE 118p.; Conference held at the National Institute of Mental Health, Chevy Chase, Maryland, September 29, 1967 AVATLABLE FROM Superintendent of Documents, Government Printing Office, Washington, D. C. 20402 ($1.25). FDPS PRICE FDPS Price MFc0.50 HC Not Available from EDRS. DESCPTPTOPS Conference Reports, *Drug Abuse, Health Education, *Lysergic Acid Diethylamide, *Medical Research, *Mental Health IDENTIFIEPS Hallucinogenic Drugs ABSTPACT This reports a conference of psychologists, psychiatrists, geneticists and others concerned with the biological and psychological effects of lysergic acid diethylamide and other hallucinogenic drugs. Clinical data are presented on adverse drug reactions. The difficulty of determining the causes of adverse reactions is discussed, as are different methods of therapy. Data are also presented on the psychological and physiolcgical effects of L.S.D. given as a treatment under controlled medical conditions. Possible genetic effects of L.S.D. and other drugs are discussed on the basis of data from laboratory animals and humans. Also discussed are needs for futher research. The necessity to aviod scare techniques in disseminating information about drugs is emphasized. An aprentlix includes seven background papers reprinted from professional journals, and a bibliography of current articles on the possible genetic effects of drugs. (EB) National Clearinghouse for Mental Health Information VA-w. Alb alb !bAm I.S. MOMS Of NAM MON tMAN IONE Of NMI 105 NUNN NU IN WINES UAWAS RCM NIN 01 NUN N ONMININI 01011110 0. -
The Iboga Alkaloids
The Iboga Alkaloids Catherine Lavaud and Georges Massiot Contents 1 Introduction ................................................................................. 90 2 Biosynthesis ................................................................................. 92 3 Structural Elucidation and Reactivity ...................................................... 93 4 New Molecules .............................................................................. 97 4.1 Monomers ............................................................................. 99 4.1.1 Ibogamine and Coronaridine Derivatives .................................... 99 4.1.2 3-Alkyl- or 3-Oxo-ibogamine/-coronaridine Derivatives . 102 4.1.3 5- and/or 6-Oxo-ibogamine/-coronaridine Derivatives ...................... 104 4.1.4 Rearranged Ibogamine/Coronaridine Alkaloids .. ........................... 105 4.1.5 Catharanthine and Pseudoeburnamonine Derivatives .. .. .. ... .. ... .. .. ... .. 106 4.1.6 Miscellaneous Representatives and Another Enigma . ..................... 107 4.2 Dimers ................................................................................. 108 4.2.1 Bisindoles with an Ibogamine Moiety ....................................... 110 4.2.2 Bisindoles with a Voacangine (10-Methoxy-coronaridine) Moiety ........ 111 4.2.3 Bisindoles with an Isovoacangine (11-Methoxy-coronaridine) Moiety . 111 4.2.4 Bisindoles with an Iboga-Indolenine or Rearranged Moiety ................ 116 4.2.5 Bisindoles with a Chippiine Moiety ... ..................................... -
Microgram Journal, Vol 2, Number 1
Washington, D. C. Office of Science and Education Vol.II,No.1 Division of Laboratory Operations January 1969 INDEXISSUE CORRECTION 11 "Structure Elucidation of 'LBJ' , by Sander W. Bellman, John W. Turczan, James Heagy and Ted M. Hopes, Micro Gram .!., 3, 6-13 (Dec. 1968) Page 7, third and fourth sentences under Discussion: Change to read: "The melting point of the acid moiety found in step (g) was 148-150°c., compared to the litera ture, v~lue of 151°c for the melting point of benzilic acid (2); thus the benzilic acid melting point gives support to the proposed structure for 'LBJ'. Spectral evidence also supports the proposed structure". MICRO-GRAMREVISION Please re-number the pages of your copies of Micro-Gram, Volume I. Re-number pages bearing printing only. Vol ume I will then be numbered from page 1, the front page of issue No. 1, through page 189 the last page of issue No. 12. To help with this task, pages contained within each issue are as follows: Issue Number Page Through 1 1 8 2 9 29 3 30 32 4 33 66 5 67 79 6 80 97 7 98 120 8 121 128 9 129 136 10 137 157 11 158 170 12 171 189 CAUTION: Use of this publication should be restricted to forensic analysts or others having a legitimate need for this material. From the Archive Library of Erowid Center http://erowid.org/library/periodicals/microgram -2- CANNABIS ,·,-...__/' Attached is a copy of 11A Short Rapid Method for the Identification of Cannabis." The method was developed by Mro H.D. -
Microgram Journal, Vol 3, Number 2
MICROGRAM Laboratory Operations Division Office Of Science And Drug Abuse Prevention BUREAU OF NARCOTICS & DANGEROUS DRUGS / U.S. DEPARTMENT OF JUSTICE / WASHINGTION, D.C. 20537 Vol.III, No. 2 March-April, 1970 STP (4-Methyl-2,5-dimethoxyamphetamine) hydrochloride was found coating the inside of capsules sent to BNDDfrom Germany. The capsules were clear, hard gelatin, standard shape size No. o. Average weight was 114 milligrams. Each capsule had a white crystalline coating on inner surface of capsule body. Apparently a measu~ed amount of solution had been placedin the cap·sule body, after which it was rotated to spread the solution on the inner surface. The substance contained 8. 7 milli grams STP (DOM)HCl per ca·psule. · These were the first STP capsules of this type seen by our laboratory. A few years ago, capsules were ob tained in the U.S. similarly coated with LSD. STP (Free Base) on laboratory filter paper, also from Germany, was seen for the first time in our laboratory. The STP spots, containing approxi mately 8 miliigrams STP base each, were 5/8 to 3/4 inch in diameter. The paper was 1\ inches square. Phencyclidine (Free Base) was recently analyzed on parsley leaves. Called "Angel DUst, 11 the phencyclidine on two samples of leaves was 2.6% and 3.6%. Approximately thirty pounds of 94% pure powder was also analyzed. (For identification of phencyclidine base, see Microgram, II, 1, p.3 (Jan 1969). IMITATIONSof well-known drug products are examined frequently in our Special Testing and Research Laboratory. Many of these are well made preparations and closely resemble the imitated product. -
Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence
NIH Public Access Author Manuscript CNS Drugs. Author manuscript; available in PMC 2013 June 09. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: CNS Drugs. 2012 March 1; 26(3): 189–204. doi:10.2165/11599770-000000000-00000. Ketamine for Treatment-Resistant Unipolar Depression: Current Evidence Sanjay J. Mathew1,2,3, Asim Shah1, Kyle Lapidus3, Crystal Clark1,2, Noor Jarun1, Britta Ostermeyer1, and James W. Murrough3,4 1Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA 2Michael E. Debakey VA Medical Center, Houston, TX, USA 3Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA 4Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA Abstract Currently available drugs for unipolar major depressive disorder (MDD), which target monoaminergic systems, have a delayed onset of action and significant limitations in efficacy. Antidepressants with primary pharmacological targets outside the monoamine system may offer the potential for more rapid activity with improved therapeutic benefit. The glutamate system has been scrutinized as a target for antidepressant drug discovery. The purpose of this article is to review emerging literature on the potential rapid-onset antidepressant properties of the glutamate NMDA receptor antagonist ketamine, an established anaesthetic agent. The pharmacology of ketamine and its enantiomer S-ketamine is reviewed, followed by examples of its clinical application in chronic, refractory pain conditions, which are commonly co-morbid with depression. The first generation of studies in patients with treatment-resistant depression (TRD) reported the safety and acute efficacy of a single subanaesthetic dose (0.5 mg/kg) of intravenous ketamine. -
Quantitative in Vivo Receptor Binding
0270-6474/85/0502-0421$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 5, No. 2, pp. 421-428 Printed in U.S.A. February1985 QUANTITATIVE IN VIVO RECEPTOR BINDING I. Theory and Application to the Muscarinic Cholinergic Receptor’ K. A. FREY, R. L. E. EHRENKAUFER, S. BEAUCAGE, AND B. W. AGRANOFF3 Neuroscience Laboratory, Department of Biological Chemistry and Division of Nuclear Medicine, The University of Michigan, Ann Arbor, Michigan 48109 Received April 2, 1984; Revised July 13, 1984; Accepted July 23, 1984 Abstract A novel approach to in vivo receptor binding experiments is presented which allows direct quantitation of binding site densities. The method is based on an equilibrium model of tracer uptake and is designed to produce a static distribution proportional to receptor density and to minimize possible confounding influences of regional blood flow, blood-brain barrier permeability, and nonspecific binding. This technique was applied to the measurement of regional muscarinic cholinergic receptor densities in rat brain using [3H]scopolamine. Specific in vivo binding of scopolamine demonstrated saturability, a pharmacologic profile, and regional densities which are consistent with interaction of the tracer with the muscarinic receptor. Estimates of receptor density obtained with the in vivo method and in vitro measurements in homogenates were highly correlated. Furthermore, reduction in striatal muscarinic receptors following ibotenic acid lesions resulted in a significant decrease in tracer uptake in vivo, indicating that the correlation between scopolamine distribution and receptor density may be used to demonstrate pathologic conditions. We propose that the general method presented here is directly applicable to investigation of high affinity binding sites for a variety of radioligands. -
Visualizza/Apri
UNIVERSITY OF CATANIA FACULTY OF PHARMACY DEPARTMENT OF PHARMACEUTICAL SCIENCES INTERNATIONAL DOCTORATE IN PHARMACEUTICAL SCIENCES XXIII Cycle SEMMELWEIS UNIVERSITY - BUDAPEST FACULTY OF PHARMACY DEPARTMENT OF ORGANIC CHEMISTRY ______________________________________________________ Dr. Antonino Grillo Design and synthesis of new vinca alkaloid derivatives as potential sigma-2 receptor ligands __________________ DOCTORATE THESIS __________________ Coordinator and Supervisor: Prof. Giuseppe Ronsisvalle Co-supervisor: Prof. Péter Mátyus ACADEMIC YEAR 2009-2010 Table of Contents INTRODUCTION 3 SIGMA RECEPTOR SUBCLASSES 5 ANATOMICAL DISTRIBUTION AND RELATED FUNCTIONS 8 NERVOUS SYSTEM 8 PERIPHERAL ORGANS 9 PROPOSED ENDOGENOUS LIGANDS FOR SIGMA RECEPTORS 11 SIGMA-1 RECEPTOR 13 CHARACTERIZATION 13 SUBCELLULAR LOCALIZATION 14 SIGNAL TRANSDUCTION MECHANISM AND MODULATORY ACTION 15 SELECTIVE SIGMA-1 LIGANDS AND PHARMACOPHORIC MODEL 16 SIGMA-2 RECEPTOR 18 CHARACTERIZATION 18 SUBCELLULAR LOCALIZATION 19 SIGMA-2 RECEPTORS AND THE REGULATION OF MOTOR FUNCTION 20 SIGMA-2 RECEPTORS AND CELL DEATH 21 SIGMA-2 LIGANDS AS PROBES FOR IMAGING IN VITRO AND IN VIVO 24 SIGMA-2 LIGANDS 27 PROPOSED PHARMACOPHORIC MODEL FOR SIGMA-2 RECEPTOR 33 IBOGAINE: PHARMACOLOGICAL PROFILE 35 IBOGAINE AND ITS RELATED ALKALOIDS: SAR 37 AIMS OF THE WORK AND DRUG DESIGN 39 INDIVIDUATION OF A NATURAL SCAFFOLD 39 SUPERIMPOSITION STUDY: VINCA-DERIVATIVES UPON IBOGAINE 41 DESIGNED LIGANDS 44 CHEMISTRY 48 RESULTS 53 FINAL REMARKS 54 EXPERIMENTAL SECTION 55 MATERIALS AND METHODS 55 MONOGRAPHIES 56 REFERENCES 79 2 Introduction Sigma receptors were first proposed in the mid-1970s thanks to the studies of Martin and co-workers (1976). They demonstrated that the mania syndrome observed on animal models, after treatment with the bezomorphanic derivative (±)-N-allyl-normetazocine (code number: (±)-SKF 10,047) (Fig. -
Selective Modification of Spontaneous Ecog Rhythms of the Cat Somesthetic Cortex by Psychoactive Drugs" Behavioral Correlates
Psychopharmacology 55,237-242 (1977) Psychopharmacology by Springer-Verlag 1977 Selective Modification of Spontaneous ECoG Rhythms of the Cat Somesthetic Cortex by Psychoactive Drugs" Behavioral Correlates JEAN-JACQUES BOUYER, LAURE DEDET, JAQUELINE VERDEAUX, and ARLETTE ROUGEUL* Laboratoire de Neurophysiotogie compar6e, Universit6 P. & M. Curie, 4 place Jussieu, 75230 Paris Cedex 05, France Abstract. Three psychoactive drugs with known central 1966; Bradley and Elkes, 1957; Rougeul et al., 1965; effects were administered to the freely moving cat in Montplaisir, 1975). On the other hand, indolalkyl- order to study their action on spontaneous rhythmic amine-type substances, in particular LSD-25, produce activities recorded from the primary somesthetic abundant rhythms typical of a drowsiness ECoG cortex, which are analogous to the rolandic mu rhyhm (Rougeul et al., 1965, 1966, 1969; Rougeul and Ver- in man. The ECoG patterns obtained are qualitatively deaux, 1972). Finally, d-amphetamine is usually be- identical to those of the normal subject, but their lieved to elicit strongly desynchronized cortical activity temporal organization is profoundly disturbed by (Bradley and Elkes, 1953). the action of the drugs. The normal ECoG consists These studies (including our own on LSD) were of three rhythmic systems with distinct frequencies usually performed without any particular attention and displays a considerable time variability. In con- to the precise location of the activities recorded. Recent trast, psychoactive drugs induce a stabilized pattern studies (Bouyer et al., 1974; Rougeul-Buser et al., with only one type (o1" at most two types) of rhythm 1975) have shown that in the normal cat spontaneous prevailing for one or several hours, which never rhythmic activities recorded from somesthetic area I occurs under normal conditions.